Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - Novartis - NIS793 (Details)

v3.22.2.2
Licensing and Other Arrangements - Novartis - NIS793 (Details)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Oct. 20, 2021
USD ($)
Oct. 21, 2020
USD ($)
Sep. 30, 2015
USD ($)
item
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2021
USD ($)
Licensing and other arrangements                    
Revenue from contracts with customers       $ 25 $ 550 $ 3,300 $ 1,094      
Novartis Note                    
Licensing and other arrangements                    
Reduction in debt obligation   $ 7,300                
Novartis International | License Agreement                    
Licensing and other arrangements                    
Agreement termination prior written notice period     180 days              
Number of performance obligations | item     1              
Cash payment received   17,700             $ 37,000  
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones $ 410,000   $ 480,000              
Revenue from contracts with customers $ 35,000 $ 25,000   0 $ 0 0 $ 0 $ 10,000    
Royalty payment period     10 years              
Contract assets       0   0       $ 0
Contract liabilities       0   0       0
Capitalized contract costs       $ 0   $ 0       $ 0